Accepted at 4:07 p.m. Mar, 13, 2024 by Ahmed7
Author: musamalik
Related Note: 1462849248763 1
Rationale for change

Don't see the need for the parenthesis

Text Text
Extra
Causes depolarization of the membrane leading to endogenous insulin release, therefore C peptide is released as well


Photo credit: Aydintay, Public domain, via Wikimedia Commons
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy




Watch Insulin, Sulfonylureas, Meglitinides, GLP-1 Agonists, DPP-4 Inhibitors
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize


Review Sulfonylureas


Physeo


Bootcamp
Watch associated Bootcamp video - Diabetes Type 2 Management
OME

Additional Resources

One by one
Empty field
#AK_Step1_v12::#B&B::08_Endocrinology::03_Pancreas::04_Treatment_of_Diabetes #AK_Step1_v12::#FirstAid::08_Endocrine::05_Pharm::01_Diabetes_mellitus_therapy::*Sulfonylureas #AK_Step1_v12::#FirstAid::08_Endocrine::05_Pharm::01_Diabetes_mellitus_therapy::*Meglitinides #AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#Pixorize::03_Pharmacology::08_Diabetes_Drugs_(Old)::05_Second-Gen_Sulfonylureas #AK_Step1_v12::#SketchyPharm::05_GI_&_Endocrine::02_Diabetes::01_Insulin,_sulfonylureas,_meglitinides,_GLP-1_agonists,_DPP-4_inhibitors #AK_Step1_v12::^Systems::Endocrine::Pharmacology #AK_Step1_v12::#AMBOSS::mVaVEj #PANCE::EOR::PEDS #AK_Step1_v12::#AMBOSS::i0aJfQ #AK_Step2_v12::#OME::01_Medicine::07_Endocrinology::06_Outpatient_Type_2_Diabetes #AK_Step1_v12::#NBME::31 #AK_Step1_v12::#Pixorize::03_Pharmacology::08_Diabetes_Drugs_(Old)::06_Meglitinides #AK_Step1_v12::#Physeo::^physeo_image_update !AK_UpdateTags::Step1decks::Zanki-Pharmacology #PANCE::ENDO::diabetes #AK_Step1_v12::#AMBOSS::3XaSBQ #AK_Step2_v12::#Resources_by_rotation::IM::ome::endo::outpatient_dm #AK_Step1_v12::#Pixorize::03_Pharmacology::08_Diabetes_Drugs_(Old)::04_First-Gen_Sulfonylureas #AK_Step1_v12::#B&B::08_Endocrinology::03_Pancreas::01_Endocrine_Pancreas #AK_Step1_v12::#OME::04_Organ_Systems::06_Endocrine::05_Pancreas::03_Diabetes_Pharmacology #AK_Step2_v12::Original_decks::Dorian::im::ome::endo::outpatient_dm #AK_Step1_v12::#AMBOSS::jma_2O #AK_Step2_v12::Original_decks::Dorian::fam::ome::endo::outpatient_dm #AK_Step1_v12::#Bootcamp::Endocrinology::07_Pancreas::09_Diabetes_Type_2_Management #AK_Step1_v12::#Physeo::09_Pharm::07_Endocrine::04_Sulfonylureas_and_Meglitinides #AK_Step2_v12::#Resources_by_rotation::FM::ome::endo::outpatient_dm #AK_Step1_v12::#OME::PreClinical::04_Organ_Systems::06_Endocrine::05_Pancreas::03_Diabetes_Pharmacology #AK_Step1_v12::^Other::^HighYield::1-HighYield #AK_Step1_v12::#UWorld::COMLEX::24766 #AK_Step2_v12::!Shelf::FM::no_dupes #AK_Step1_v12::#UWorld::Step::1655 #AK_Step2_v12::#B&B::04_Endocrinology::03_Diabetes::05_Diabetes_Treatment #AK_Step2_v12::!Shelf::IM::no_dupes #AK_Step2_v12::#AMBOSS::mVaVEj #AK_Step1_v12::#Pixorize::03_Pharmacology::07_Diabetes_Drugs_(New)::07_Sulfonylureas